research Effectiveness of baricitinib in severe alopecia areata in real life: a retrospective study of 87 patients.
Baricitinib is effective and safe for treating severe alopecia areata.
Search
for
Sort by
Research
300-330 / 1000+ results
research Case Series and Literature Review on Tofacitinib for Treating Severe Alopecia Areata
Tofacitinib is effective and safe for treating severe alopecia areata.
research Baricitinib Effectiveness in JAKi‐Naïve and Tofacitinib‐Exposed Patients: A Prospective Study in Alopecia Areata
Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
research Effectiveness of baricitinib in severe alopecia areata in real life: a retrospective study of 87 patients
Baricitinib is effective and safe for treating severe alopecia areata.
research 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
research A locus on distal chromosome 10 (ahl4) affecting age-related hearing loss in A/J mice
Scientists found a gene in mice that causes early hearing loss.
research Pressure alopecias: A review
Pressure-induced hair loss is rare, often reversible, and early diagnosis is crucial to prevent complications.
research Alopecia areata (AA)
About half of people with mild alopecia areata see hair regrowth in a year, but relapses are common.
research Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients
Different treatments for Hidradenitis suppurativa range from antibiotics and hormonal therapies to surgery, depending on severity.
research A simple method using ex vivo culture of hair follicle tissue to investigate intrinsic circadian characteristics in humans
Researchers developed a way to study human body clocks using hair tissue, which works similarly in both healthy and dementia patients.
research Novel association of trichothiodystrophy with autoimmune thyroiditis and autoimmune hemolytic anemia: A case report
A child with trichothiodystrophy also had autoimmune thyroiditis and anemia, which is a new finding.
research Tofacitinib therapy for children with severe alopecia areata
Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
Deuruxolitinib is FDA-approved for treating severe alopecia areata.
research Oral Tofacitinib for the Management of Moderate to Severe Alopecia Areata in Children and Adolescents: A Retrospective Study of 36 Patients
Tofacitinib helps hair regrow in some kids with severe alopecia areata, but more research is needed on long-term effects.
research Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
research Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
Baricitinib significantly regrows hair in teens with severe alopecia areata.
research Laser-Assisted Drug Delivery: A Systematic Review of Safety and Adverse Events
Laser-assisted drug delivery is generally safe with mostly mild side effects.
research Vitamin D and the Skin: A Review for Dermatologists
Vitamin D is important for skin health, but more research is needed to understand its full effects and treatment potential.
research Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
research Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
Baricitinib is generally safe for long-term use in treating severe alopecia areata.
research Efficacy of the phosphodiesterase-4 inhibitor, apremilast, in a patient with severe alopecia areata
The document did not conclude on apremilast's effectiveness for severe alopecia areata.
research Efficacy of intradermal minoxidil 5% injections for treatment of patchy non-severe alopecia areata
Minoxidil injections can speed up hair regrowth in non-severe patchy hair loss, but combining it with steroids doesn't improve results.
research Effectiveness of Baricitinib for Nasal, Genital, and Beard Hair Regrowth in Patients with Severe Alopecia Areata: 12-Month Outcomes from a Prospective Observational Study
Baricitinib significantly regrows hair in nasal, genital, and beard areas for severe alopecia areata.
research Long‐Term Real‐World Outcomes of Baricitinib in Severe Alopecia Areata: A 104‐Week Retrospective Analysis From a Single Institute
Baricitinib is effective and safe for long-term treatment of severe alopecia areata.
research Hidradenitis Suppurativa in Children and Adolescents: A Review of Treatment Options
More pediatric-specific research and guidelines are needed to improve hidradenitis suppurativa treatment in children and adolescents.
research Characterizing Lipid Changes and Use of Lipid-Lowering Medications in Patients With Alopecia Areata Treated With Baricitinib: Integrated Results From the BRAVE-AA1 and -AA2 Clinical Trials
Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.
research Long-COVID Clinical Features and Risk Factors: A Retrospective Analysis of Patients from the STOP-COVID Registry of the PoLoCOV Study
70.7% of patients had long-COVID symptoms like fatigue, cough, and brain fog three months after recovery.
research Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution
Skin side effects from melanoma immunotherapy are common and may indicate better survival.
research Pediatric Clinical Trial Program in Progress: A Phase 3 Study and Long-term Extension Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 years of Age With Severe Alopecia Areata
Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
research Table 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx
Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.